chromocell.com (CHRO) - Company Sales
Chromocell Therapeutics faces threats due to a lack of revenue and a dependence on investments. The company's sales volume demonstrates current demand dynamics, where the 0.00 mark reflects the latest data. Management is currently focusing on initial analgesic tests, while the company strives to develop safe non-opioid treatments for chronic pain.
Analytical breakdowns for Chromocell Therapeutics Corporation (CHRO)
- market price and analyst price targets:
- market capitalization indicators:
- balance sheet equity data:
- debt and solvency information:
Debt to Equity Chromocell Therapeutics|CHRO - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Chromocell Therapeutics|CHRO - Company Total Debt|Debt to Book Capital Chromocell Therapeutics Corp|CHRO - Company Long-Term Debts|Company Short-Term Loans and Borrowings Chromocell Therapeutics|Immediate Liquidity chromocell.com
- business earnings and investment ratios data:
CHRO - Company Net Income|Expected Net Income Chromocell Therapeutics|CHRO - P/E Multiple|Forward P/E Multiple Chromocell Therapeutics Corp|CHRO - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Chromocell Therapeutics Corp|CHRO - Operating profit EBITDA|Net earnings per one share for the last twelve months Chromocell Therapeutics|CHRO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth chromocell.com|CHRO - Net earnings per share growth this year|Projected earnings per share increase next year Chromocell Therapeutics
- sales volume and revenue indicators:
General company analysis:Chromocell Therapeutics, CHRO
Revenue reflects the aggregate cash flow from asset realization, serving as an integral indicator of management efficiency and fundamental business stability. The daily price action on the sales revenue chart for Chromocell Therapeutics (CHRO) demonstrates the capitalization's sensitivity to financial results, which is critical for Chromocell Therapeutics (CHRO) as outsourcing production to CMO facilities minimizes operating expenses and the risks of capacity downtime.
Key competitors
Company Sales Volume BIIB (Biogen)|Company Revenue Neurocrine Biosciences, Inc. (NBIX)|Company Revenue RGC (Regencell Bioscience Ltd)|Axsome Therapeutics, Inc. - Company Sales|ACAD (ACADIA Pharmaceuticals Inc) - Company Annual Revenue|Xenon Corp - Revenue and Sales Volume|Company Sales Revenue VKTX (Viking Therapeutics)|Supernus Pharmaceuticals (SUPN) - Company Revenue|Company Annual Revenue CPRX (Catalyst Pharmaceuticals, Inc.)|Company Revenue Denali Therapeutics Inc|Company Total Revenue Harmony Corp HRMY|Revenue and Sales Volume BHVN|Company Sales Amylyx Pharmaceuticals AMLX|Revenue and Sales Volume TRVI (Trevi Corp)|Company Gross Revenue Praxis Precision Medicines, Inc. (PRAX)|Anavex Life Sciences Corp - Revenue and Sales Volume|CeriBell Corp (CBLL) - Company Sales|Prothena Corp (PRTA) - Company Revenue|Company Total Revenue Alector Inc. (ALEC)|Company Sales ANNX|omeros.com (OMER) - Company Gross Revenue|Company Revenue Neurogene Inc. (NGNE)|ACIU (AC Immune Inc) - Company Sales Revenue|Revenue and Sales Volume VYGR (voyagertherapeutics.com)|Company Gross Revenue Neumora Therapeutics (NMRA)|SCLX - Company Revenue|Company Total Sales Volume Tevogen Bio Holdings Inc. (TVGN)|Alpha Cognition (ACOG) - Company Revenue|CGTX - Company Gross Revenue|IKT (inhibikase.com) - Revenue and Sales Volume|cassavasciences.com (SAVA) - Company Gross Revenue|Company Sales ASRT (Assertio Therapeutics)|Company Gross Revenue Coya Therapeutics|Vistagen - Company Sales|ovidrx.com (OVID) - Company Total Revenue|Acumen Pharmaceuticals - Revenue and Sales Volume|Company Total Revenue cervomed.com|ATHE: Revenue and Sales Volume|Clene Inc - Company Sales Revenue|Company Revenue PepGen|JUNS (Jupiter Neurosciences Inc) - Company Total Sales|Company Sales RLMD (Relmada Corp)|annovisbio.com - Company Sales Volume|Company Revenue gracetx.com GRCE|AIFF (Firefly Neuroscience, Inc.) - Company Annual Revenue|KLTO - Company Revenue|Company Total Revenue NeuroSense Therapeutics Ltd|Reviva Pharmaceuticals (RVPH) - Company Revenue|Company Sales Volume MTVA|Company Sales NRXS|Company Sales Helius Medical (HSDT)|Revenue and Sales Volume PASG|Neuphoria Therapeutics - Company Sales Volume|Company Revenue Minerva Neurosciences, Inc. NERV|Revenue and Sales Volume Athira Pharma ATHA|ADXN: Company Sales|Company Total Revenue Alzamend Neuro|Cyclerion Therapeutics Inc. (CYCN) - Company Revenue|Company Total Revenue Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Revenue and Sales Volume|Company Sales Cortigent (CRGT)|Revenue and Sales Volume ATXI|BCLI - Company Total Revenue|Revenue and Sales Volume CARA (Cara Therapeutics, Inc)|Revenue and Sales Volume Eliem Therapeutics ELYM|ITCI: Company Sales|LBPH: Company Revenue|MRNS (Marinus Pharmaceuticals, Inc.) - Company Sales|NKGen - Company Sales Revenue|Company Revenue NeuroBo Pharmaceuticals, Inc.|Revenue and Sales Volume Sage Therapeutics Inc|Revenue and Sales Volume SNPX|TRVN - Company Total Revenue|Company Revenue vigilneuro.com VIGL|Company Gross Revenue Anew Medical (WENA)|cerevel.com - Revenue and Sales Volume
